logo
Gene mutation found in the bacterium behind the Black Death helped plague conquer the world, scientists say

Gene mutation found in the bacterium behind the Black Death helped plague conquer the world, scientists say

CNN2 days ago

One of the bleakest periods in medieval Europe was the plague pandemic known as the Black Death, which killed at least 25 million people in just five years. But the disease didn't stop there. The plague adapted to keep its hosts alive longer, so it could spread farther and keep infecting people for centuries, and researchers now say they've discovered how.
The disease is caused by the bacterium Yersinia pestis, which has been circulating among human populations for at least 5,000 years. The pathogen has fueled three major plague pandemics since the first century AD, and though its deadliest years appear to be behind us, plague hasn't disappeared. Cases still occur a few times a year in Asia, South America and the United States and more commonly in parts of Africa, according to the Cleveland Clinic, and can be treated with antibiotics.
Scientists are still searching for answers about how Y. pestis evolved and dispersed, but recent analysis of ancient and modern Y. pestis samples revealed how plague managed to persist among humans for hundreds of years after pandemic waves petered out. After an initial period of high infection rates and rapid mortality — killing infected people within three days — changes to just one gene in the bacterium produced new strains that were less deadly and more transmissible, according to research published Thursday in the journal Science.
Those weakened strains eventually went extinct; the dominant lineage of today's Y. pestis is the deadlier variety, the study authors reported. However, these findings about historic instances of Y. pestis adaptation could provide important clues to help scientists and physicians manage modern plague outbreaks.
Plague's most common form is bubonic plague, which causes painful swelling in lymph nodes and spreads among people through bites from fleas hitchhiking on infected rats. An outbreak of bubonic plague from 1347 to 1352 in Europe famously killed about 30% to 50% of the continent's population. But the earliest known bubonic plague outbreak — the Plague of Justinian — took hold in the Mediterranean Basin and lasted from AD 541 to AD 544. Another plague outbreak emerged in China in the 1850s and sparked a major epidemic in 1894. Scientists view modern plague cases as part of this third pandemic.
For the new study, scientists collected ancient samples of Y. pestis from human remains dating back to about 100 years after the appearance of the first and second plague pandemics, sampling remains from Denmark, Europe and Russia. After reconstructing the genomes of these plague strains, they compared them with older, ancient strains that dated back to the start of plague pandemics.
The researchers also examined more than 2,700 genomes of modern plague samples from Asia, Africa, and North and South America. One of the study coauthors, Jennifer Klunk, is a product scientist at Daciel Arbor Biosciences, a biotechnology company in Michigan that provided synthetically created molecules for the experiments, but there was no financial gain associated with the research.
The researchers found that their newly reconstructed genomes from 100 years into the first two plague pandemics had fewer copies of a gene called pla, which has been recognized for decades as one of the factors that made plague so deadly, according to the study's co-lead author Ravneet Sidhu, a doctoral student in the McMaster Ancient DNA Centre at McMaster University in Ontario, Canada.
Pla encodes an enzyme that interacts with host proteins, 'and one of the functions that it carries out is in breaking down blood clots,' Sidhu told CNN. This ability helps Y. pestis spread into the host's lymph nodes, where it replicates before attacking the rest of the body.
'Not every function of this gene is fully known,' Sidhu added. However, prior studies by other researchers linked pla to severity of illness caused by both bubonic and pneumonic plague — an airborne form of the disease that affects the lungs, she said.
While the reconstructed strains showed fewer copies of the pla gene, the scientists were still uncertain whether that would directly affect how deadly the disease could be. So they tested strains of reduced-pla bubonic plague on mice, and found that survival rates for this type of plague were 10 to 20 percent higher in those experiment subjects than in mice infected with Y. pestis that had a normal amount of the pla gene. It also took the reconstructed bubonic strain about two days longer to kill its hosts.
'The paper presents a strong argument that depletion, but not total loss, of Pla (the enzyme produced by the pla gene) is part of the evolution of the plague pathogen and may help explain the decline of plague in the second pandemic commonly known as the Black Death,' said Dr. Deborah Anderson, a professor of veterinary pathobiology at the University of Missouri's College of Veterinary Medicine. Anderson, who was not involved in the new research, investigates the virulence of plague, and these findings could shed light on transmission patterns in modern cases, she told CNN in an email.
'Our laboratory studies the flea-rodent cycle and we have collaborators who conduct field research in areas that experience annual or occasional plague outbreaks in the wild,' Anderson said.
'There are nearly 300 rodent species that can transmit Yersinia pestis, and today, burrowing rodents such as prairie dogs or ground squirrels are considered key animal hosts that experience outbreaks of disease,' she added. 'After reading this paper, we will pay closer attention to Pla in the future to see if there continues to be a role for its expression in driving the explosive outbreaks of plague in the animal populations.'
Mathematical models suggested how this might have played out in human populations centuries ago, leading to an 'epidemic burnout' about 100 years after a bubonic plague outbreak.
In a pandemic's early stages, infections were swift, and death came quickly for both rats and humans. Over time, as dense rat populations thinned out, selective pressures favored the emergence of a less deadly strain of Y. pestis, with fewer copies of the pla gene. Rat hosts infected with this new strain would have a little more time to carry the disease, potentially enabling them to infect more rats — and more people.
'They suggest a model that can be readily pursued in the laboratory that may help explain the spread of plague today in the wild,' Anderson said.
These weaker strains of the disease eventually sputtered out and went extinct. In the modern samples, the researchers found just three examples of strains with reduced pla genes, from Vietnam: one from a human subject and two from black rats (Rattus rattus).
'We've been able to do this really cool interdisciplinary study between the modern and ancient data and marry these things that have been happening throughout (the plague's) long evolutionary history,' Sidhu said. 'It could be interesting to see how future researchers continue to try and bridge that gap between the modern third pandemic and those first and second ancient pandemics, to see other similarities. Because there aren't a lot of ancient pathogens that we have as much data on, as we do for Yersinia pestis.'
One of the unusual features of plague pandemics is their persistence, and understanding how Y. pestis changed its infection patterns and survived over time could shed light on the adaptive patterns of modern pandemics such as Covid-19, she added.
'Even if we aren't experiencing it to the amount that we were in 2020 or 2021, the pathogen is in the background — still evolving and persisting.'
Mindy Weisberger is a science writer and media producer whose work has appeared in Live Science, Scientific American and How It Works magazine. She is the author of 'Rise of the Zombie Bugs: The Surprising Science of Parasitic Mind Control' (Hopkins Press).

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

FDA's New AI Tool Cuts Review Time From 3 Days To 6 Minutes
FDA's New AI Tool Cuts Review Time From 3 Days To 6 Minutes

Forbes

timean hour ago

  • Forbes

FDA's New AI Tool Cuts Review Time From 3 Days To 6 Minutes

AI at the FDA getty The U.S. Food and Drug Administration announced this week that it deployed a generative AI tool called ELSA (Evidence-based Learning System Assistant), across its organization. After a low-profile pilot that delivered measurable gains, the system is now in use by staff across the agency, several weeks ahead of its original schedule. Dr. Marty Makary, the FDA's commissioner, shared a major outcome. A review task that once took two or three days now takes six minutes. 'Today, we met our goal ahead of schedule and under budget,' said Makary. 'What took one scientific reviewer two to three days [before] The FDA has thousands of reviewers, analysts, and inspectors who deal with massive volumes of unstructured data such as clinical trial documents, safety reports, inspection records. Automating any meaningful portion of that stack creates outsized returns. ELSA helps FDA teams speed up several essential tasks. Staff are already using it to summarize adverse event data for safety assessments, compare drug labels, generate basic code for nonclinical database setup, and identify priority sites for inspections, among other tasks. This last item, using data to rank where inspectors should go, could have a real-world impact on how the FDA oversees the drug and food supply chain and impacts on how the FDA delivers its services. Importantly, however, the tool isn't making autonomous decisions without a human in the loop. The system prepares information so that experts can decide faster. It cuts through the routine, not the judgment. One of the biggest questions about AI systems in the public sector revolves around the use of data and third party AI systems. Makary addressed this directly by saying that 'All information stays within the agency. The AI models are not being trained on data submitted by the industry.' That's a sharp contrast to the AI approaches being taken in the private sector, where many large language models have faced criticism over training on proprietary or user-submitted content. In the enterprise world, this has created mounting demand for "air-gapped" AI solutions that keep data locked inside the company. That makes the FDA's model different from many corporate tools, which often rely on open or external data sources. The agency isn't building a public-facing product. It's building a controlled internal system, one that helps it do its job better. Federal departments have been slow to move past AI experimentation. The Department of Veterans Affairs has started testing predictive tools to manage appointments. The SEC has explored market surveillance AI for years. But few have pushed into full and widespread production. The federal government has thousands of employees processing huge volumes of information, most of it unstructured sitting in documents, files, and even paper. That means AI is being focused most on operational and process-oriented activities. It's shaping up to be a key piece of how agencies process data, make recommendations, and act. Makary put it simply that ELSA is just the beginning for AI adoption within the FDA. 'Today's rollout of ELSA will be the first of many initiatives to come,' he said. 'This is how we'll better serve the American people.'​​

Should We Test Babies for Incurable Diseases?
Should We Test Babies for Incurable Diseases?

New York Times

timean hour ago

  • New York Times

Should We Test Babies for Incurable Diseases?

In every postpartum hospital unit across the country, 1-day-old babies undergo the same ritual: A nurse pricks the newborn's heel and stamps tiny drops of blood onto a paper filter, which is then sent off for a standard screening panel. Today, that panel checks for unusual bio-markers that may indicate a rare but treatable disease like sickle cell anemia or cystic fibrosis. But what if that same dried blood spot could tell you about the baby's risk of developing certain conditions later in life — some with no method of prevention or cure? What if that heel prick could tell you that the baby was almost certainly going to be diagnosed with autism by the time they turned 5? Or that the child would be more likely to develop breast cancer as an adult? Would you want to know? Would she? These questions are no longer hypothetical. Tens of thousands of parents have sought such insights by enrolling their newborns in research projects that examine the baby's genome — the full blueprint for her growing body. As the cost of sequencing plummets, the practice of analyzing hundreds of genes in healthy babies is quietly on the rise, ushering in new questions about where to draw the boundaries of knowledge — and who should get to decide. Scientifically speaking, the possibilities are almost endless. Since virtually every disease has some basis in our genes, the full genome — with three billion base pairs, coding some 20,000 genes — contains a wealth of data to be mined for lifesaving intel and gut-wrenching secrets. But the experts are divided. Some say that revealing a risk of an incurable illness will only put parents in distress, bombarding them with despairing predictions for their young child's life. Others believe any data about diseases that arise in adulthood, like breast or colon cancer, must be excluded, since they violate that future adult's privacy and autonomy — in other words, the right not to know. Want all of The Times? Subscribe.

Continuing Metformin Reduces PCOS Pregnancy Risks
Continuing Metformin Reduces PCOS Pregnancy Risks

Medscape

time2 hours ago

  • Medscape

Continuing Metformin Reduces PCOS Pregnancy Risks

Continuing metformin throughout the first trimester in women with polycystic ovary syndrome (PCOS) showed the potential to reduce miscarriage risk (odds ratio [OR], 0.64) and increase clinical pregnancy rates (OR, 1.57) compared with placebo. A meta-analysis of 12 randomized controlled trials involving 1708 women suggested that stopping metformin at pregnancy confirmation might be less beneficial than continuation through the first trimester. METHODOLOGY: Researchers conducted a systematic review and meta-analysis of randomized controlled trials evaluating metformin started preconception and continued at least until positive pregnancy test compared with placebo or no treatment in women with PCOS. The analysis included 12 trustworthy studies with 1708 participants, with trials conducted across 14 countries spanning five continents, all graded as low to moderate quality evidence. The primary outcome measure focused on miscarriage rate, defined as pregnancy loss prior to 20 completed weeks of gestation, while secondary outcomes included clinical pregnancy and live birth rates. Investigators performed indirect comparisons between treatment groups using the Bucher technique to evaluate clinical pregnancy, miscarriage, and live birth rates for metformin treatment continued throughout first trimester vs stopped at a positive pregnancy test. TAKEAWAY: Women receiving preconception metformin continued throughout the first trimester had higher clinical pregnancy rates (OR, 1.57; 95% CI, 1.11-2.23), potential reduction in miscarriage (OR, 0.64; 95% CI, 0.32-1.25), and possible increase in live birth (OR, 1.24; 95% CI, 0.59-2.61) compared with placebo or no treatment. Participants who stopped metformin once pregnant showed an increased clinical pregnancy rate (OR, 1.35; 95% CI, 1.01-1.80) but suggested higher miscarriage risk (OR, 1.46; 95% CI, 0.73-2.90) compared with placebo or no treatment. Indirect comparisons consistently favored continuing metformin through first trimester vs stopping at pregnancy confirmation for clinical pregnancy (OR, 1.16; 95% CI, 0.74-1.83), miscarriage (OR, 0.44; 95% CI, 0.17-1.16), and live birth (OR, 1.14; 95% CI, 0.41-3.13). IN PRACTICE: 'Women with PCOS have been shown to have a fivefold increased risk per year of developing insulin resistance and subsequent type 2 diabetes. Insulin resistance has been shown to be independently associated with a higher risk of miscarriage. Metformin acts by decreasing gluconeogenesis, lipogenesis and enhancing glucose uptake, all of which in turn reduce insulin resistance,' wrote the authors of the study. SOURCE: The study was led by James Cheshire, PhD, Birmingham Women's and Children's NHS Foundation Trust in Birmingham, England. It was published online in American Journal of Obstetrics and Gynecology . LIMITATIONS: According to the authors, the main limitation was the inherent heterogeneous nature of the study population and the overall low quality of evidence. Women with PCOS have different phenotypes and varying degrees of hyperandrogenism and insulin resistance, which could not be accounted for in the analyses. Additionally, many studies did not subdivide pregnancy outcome data by body mass index (BMI), preventing meaningful analyses in BMI subgroups. The limited outcome data in spontaneously conceiving populations (only 30 women from two studies) make it difficult to extrapolate findings to this group. DISCLOSURES: The authors reported having no conflicts of interest. The study received no external funding.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store